| Title: |
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab |
| Authors: |
Vallejo-Vaz, AJ; Leiter, LA; Del Prato, S; Taskinen, M-R; Müller-Wieland, D; Bujas-Bobanovic, M; Letierce, A; Mandel, J; Samuel, R; Ray, KK |
| Source: |
1674 ; 1663 |
| Publisher Information: |
SAGE Publications |
| Publication Year: |
2020 |
| Collection: |
Imperial College London: Spiral |
| Subject Terms: |
Science & Technology; Life Sciences & Biomedicine; Cardiac & Cardiovascular Systems; Cardiovascular System & Cardiology; Alirocumab; proprotein convertase subtilisin; kexin type 9; non-high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; triglycerides; goal attainment; CARDIOVASCULAR-RISK PATIENTS; NON-HDL CHOLESTEROL; REMNANT CHOLESTEROL; INHIBITOR ALIROCUMAB; RESIDUAL RISK; EFFICACY; SAFETY; DISEASE; HYPERCHOLESTEROLEMIA; EZETIMIBE; proprotein convertase subtilisin/kexin type 9 |
| Subject Geographic: |
England |
| Description: |
AIMS: Guidelines recommend targeting non-high-density lipoprotein cholesterol to reduce cardiovascular risk. We assessed the impact of baseline triglycerides on non-high-density lipoprotein cholesterol goal attainment in 10 phase 3 trials with alirocumab versus control (n = 4983). METHODS: Trials were grouped into four pools based on alirocumab dose (75-150 mg every 2 weeks), control (placebo/ezetimibe) and statin use. Baseline triglyceride quintiles were built within each pool. Non-high-density lipoprotein cholesterol goal attainment (very high risk: |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
European Journal of Preventive Cardiology; http://hdl.handle.net/10044/1/77262 |
| DOI: |
10.1177/2047487320905185 |
| Availability: |
http://hdl.handle.net/10044/1/77262; https://doi.org/10.1177/2047487320905185 |
| Rights: |
© The European Society of Cardiology 2020. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). ; https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.8DB7B01B |
| Database: |
BASE |